Low acylation stimulating protein levels are associated with cardiometabolic disorders-secondary to autoimmune activation?

Basit Öğe Kaydı
dc.authoridAdemoglu, Evin/0000-0003-2933-3119
dc.authoridKaradeniz, Yusuf/0000-0002-6113-3259
dc.authoridAltay, Servet/0000-0001-7112-3970
dc.authorwosidAdemoglu, Evin/AAD-8990-2020
dc.authorwosidKaradeniz, Yusuf/JAC-5120-2023
dc.authorwosidYuksel, Murat/B-7287-2013
dc.authorwosidKaradeniz, Yusuf/AAD-2218-2022
dc.authorwosidCan, Günay/AAB-1669-2020
dc.authorwosidAltay, Servet/C-1387-2018
dc.contributor.authorOnat, Altan
dc.contributor.authorAltay, Servet
dc.contributor.authorYuksel, Murat
dc.contributor.authorKaradeniz, Yusuf
dc.contributor.authorCan, Gunay
dc.contributor.authorYuksel, Husniye
dc.contributor.authorAdemoglu, Evin
dc.date.accessioned2024-06-12T10:50:38Z
dc.date.available2024-06-12T10:50:38Z
dc.date.issued2017
dc.departmentTrakya Üniversitesien_US
dc.description.abstractObjective: We investigated the possible association of serum acylation stimulating protein (ASP) with cardiometabolic disorders and the evidence of autoimmune activation. Methods: Population-based randomly selected 1024 participants were cross-sectionally and prospectively analyzed. ASP concentrations were measured with a validated ELISA kit. Correlations were sought separately in subjects with no cardiometabolic disorders (n=427) designated as healthy. Results: ASP was positively correlated with total testosterone and inversely correlated with platelet activating factor (PAF), PAF-acetylhydrolase (AH), in each gender, and positively correlated in healthy men with lipoprotein [Lp](a) and apolipoprotein B. Correlations of ASP with PAF values =22 nmol/L were abolished, contrasted to a strongly inverse one in subjects with PAF Conclusion: Findings can be explained by the notion of operation of immune responses against both ASP and oxidized PAF-like lipids of Lp(a) to yield for reduced values and increased likelihood of cardiometabolic disorders.en_US
dc.identifier.doi10.14744/AnatolJCardiol.2016.7024
dc.identifier.endpage106en_US
dc.identifier.issn2149-2263
dc.identifier.issn2149-2271
dc.identifier.issue2en_US
dc.identifier.pmid27599666en_US
dc.identifier.scopus2-s2.0-85015309341en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage97en_US
dc.identifier.urihttps://doi.org/10.14744/AnatolJCardiol.2016.7024
dc.identifier.urihttps://hdl.handle.net/20.500.14551/18076
dc.identifier.volume17en_US
dc.identifier.wosWOS:000396901400005en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherTurkish Soc Cardiologyen_US
dc.relation.ispartofAnatolian Journal Of Cardiologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectAcylation Stimulating Proteinen_US
dc.subjectAutoimmunityen_US
dc.subjectType-2 Diabetesen_US
dc.subjectLipoprotein(A)en_US
dc.subjectMetabolic Syndromeen_US
dc.subjectPlatelet Activating Factoren_US
dc.subjectPhospholipidsen_US
dc.subjectMetabolic Syndromeen_US
dc.subjectPhospholipase A(2)en_US
dc.subjectComplement C3en_US
dc.subjectDiseaseen_US
dc.subjectLipidsen_US
dc.subjectDefinitionen_US
dc.subjectHumansen_US
dc.subjectWomenen_US
dc.subjectRisken_US
dc.titleLow acylation stimulating protein levels are associated with cardiometabolic disorders-secondary to autoimmune activation?en_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu